The company could rival Vertex and Lilly in the burgeoning market for non-opioid, ion-channel-blocking pain drugs. Its ...

Early indicators from a compassionate use plan led analysts to hike projections for daraxonrasib. Elsewhere, Intellia believes it’s answered a key safety question and Arrowhead moved to catch a rival.

Regulators say the telehealth company illegally shared patients’ health data with advertisers and misled its customers. Hims ...

The clearance paves the way for the first preventive flu shot based on mRNA technology and completes a dramatic regulatory ...

Alkeus brought to late-stage testing a Stargardt disease therapy that former executive chairman and Vertex founder Josh Boger ...

Braveheart is one of five biotechnology firms that made plans to price an IPO this week, bringing in total what could ...

Schwartz will step into an agency that has been without a permanent leader for almost a year amid RFK Jr.’s tumultuous tenure ...

Some analysts see warning signs in crucial drug launches from Gilead and Merck, while an important trial readout could change ...

An FDA nod mostly clears the way for Orzeyful to enter, by Wall Street estimates, a multibillion-dollar market for drugs that ...

The accelerated clearance follows two earlier rejections and the support of an advisory panel that disputed the arguments of FDA scientists.

The transaction combines two companies marketing nearly a dozen neurological drugs that bring in steady, but not blockbuster ...

A research disappointment and a miss on Wegovy pill sales hurt Novo, while Lilly’s injectable franchise once again surpassed ...